Articles:

Laura V. July, Eliana Beraldi, Alan So, Ladan Fazli, Kenneth Evans, John C. English, and Martin E. Gleave

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo
Mol Cancer Ther 2004 3: 223-232. [Abstract] [Full Text] [PDF]  

Sarah Welsh, Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, and Garth Powis

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1
Mol Cancer Ther 2004 3: 233-244. [Abstract] [Full Text] [PDF]  

Chunhua Qin, Derek Morrow, Jessica Stewart, Kyle Spencer, Weston Porter, Roger Smith, III, Timothy Phillips, Maen Abdelrahim, Ismael Samudio, and Stephen Safe

A new class of peroxisome proliferator-activated receptor (PPAR) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes
Mol Cancer Ther 2004 3: 247-260. [Abstract] [Full Text] [PDF]  

James Turkson, Joon S. Kim, Shumin Zhang, Jing Yuan, Mei Huang, Matthew Glenn, Eric Haura, Said Sebti, Andrew D. Hamilton, and Richard Jove

Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity
Mol Cancer Ther 2004 3: 261-269. [Abstract] [Full Text] [PDF]  

Yi Huang, Yong Fang, Jinmin Wu, Jennifer M. Dziadyk, Xueming Zhu, Meihua Sui, and Weimin Fan

Regulation of Vinca alkaloid-induced apoptosis by NF-B/IB pathway in human tumor cells
Mol Cancer Ther 2004 3: 271-277. [Abstract] [Full Text] [PDF]  

Ashish M. Kamat, Takashi Karashima, Darren W. Davis, Laura Lashinger, Menashe Bar-Eli, Randall Millikan, Yu Shen, Colin P. N. Dinney, and David J. McConkey

The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo
Mol Cancer Ther 2004 3: 279-290. [Abstract] [Full Text] [PDF]  

Sandra Huguenin, Francis Vacherot, Laurence Kheuang, Jocelyne Fleury-Feith, Marie-Claude Jaurand, Manlio Bolla, Jean-Pierre Riffaud, and Dominique K. Chopin

Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines
Mol Cancer Ther 2004 3: 291-298. [Abstract] [Full Text] [PDF]  

Tong Wu, Jing Leng, Chang Han, and Anthony Jake Demetris

The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells
Mol Cancer Ther 2004 3: 299-307. [Abstract] [Full Text] [PDF]  

Masumi Suzui, Masahito Shimizu, Muneyuki Masuda, Jin T. E. Lim, Naoki Yoshimi, and I. Bernard Weinstein

Acyclic retinoid activates retinoic acid receptor ß and induces transcriptional activation of p21^CIP1 in HepG2 human hepatoma cells
Mol Cancer Ther 2004 3: 309-316. [Abstract] [Full Text] [PDF]  

Yih Lin Chung, Ae-June Wang, and Lin-Fen Yao

Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy
Mol Cancer Ther 2004 3: 317-325. [Abstract] [Full Text] [PDF]  

Swarajit Kumar Biswas, Jie Huang, Shalini Persaud, and Alakananda Basu

Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells
Mol Cancer Ther 2004 3: 327-334. [Abstract] [Full Text] [PDF]  

Jianzhong Huang, Jason S. Frischer, Tamara New, Eugene S. Kim, Anna Serur, Alice Lee, Angela Kadenhe-Chiwishe, Daniel A. Pollyea, Akiko Yokoi, Jocelyn Holash, George D. Yancopoulos, Jessica J. Kandel, and Darrell J. Yamashiro

TNP-470 promotes initial vascular sprouting in xenograft tumors
Mol Cancer Ther 2004 3: 335-343. [Abstract] [Full Text] [PDF]  

Kapil Mehta, Larry Ocanas, Fabio Malavasi, John W. Marks, and Michael G. Rosenblum

Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells
Mol Cancer Ther 2004 3: 345-352. [Abstract] [Full Text] [PDF]  

Florence I. Raynaud, Peter M. Fischer, Bernard P. Nutley, Phyllis M. Goddard, David P. Lane, and Paul Workman

Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis
Mol Cancer Ther 2004 3: 353-362. [Abstract] [Full Text] [PDF]  

Commentary:

Kenneth D. Tew

Small molecule inhibition of hypoxia inducible factor-1: A viable therapeutic approach?
Mol Cancer Ther 2004 3: 245-246. [Full Text] [PDF]  

Minireview:

Morag C. E. McFadyen, William T. Melvin, and Graeme I. Murray

Cytochrome P450 enzymes: Novel options for cancer therapeutics
Mol Cancer Ther 2004 3: 363-371. [Abstract] [Full Text] [PDF]  

Tomasz M. Beer and Anne Myrthue

Calcitriol in cancer treatment: From the lab to the clinic
Mol Cancer Ther 2004 3: 373-381. [Abstract] [Full Text] [PDF]  

Letters to the Editor:

Lucio Tentori, Grazia Graziani, Dina Chelouche Lev, and Menashe Bar-Eli

Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: A possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753–63.
Mol Cancer Ther 2004 3: 383-384. [Full Text] [PDF]  

To see an article, click its [Full Text] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.